Immunogen (IMGN) Tops Q2 EPS by 21c

Immunogen (NASDAQ: IMGN) reported Q2 EPS of $0.16, $0.21 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $48.3 million versus the consensus estimate of $37.3 million.

Financial Guidance for Fiscal Year 2015

ImmunoGen’s financial guidance remains unchanged from that issued in October 2014. ImmunoGen expects: its revenues to be between $100 million and $105 million; its operating expenses to be between $160 million and $165 million; its net loss to be between $60 million and $65 million; its cash used in operations to be between $55 million and $60 million; and its capital expenditures to be between $7 million and $9 million. Cash and marketable securities at June 30, 2015 are anticipated to be between $75 million and $85 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
• Red River Bancshares, Inc. (RRBI) Tops Q3 EPS by 7c
• Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81